Sanofi, the French multinational pharmaceutical company, is the highlight of several important developments in the biotech industry. Recently, the company had a conclusive end to its legal strain with Amgen over the therapies Praluent and Repatha. Moreover,
Sanofi and the NAACP teamed up to address health disparities across the U.S. In another major agreement,
Sanofi secured a licensing deal worth $1.53 billion for a blood cancer drug from Sino Biopharm's unit.
A crucial change in the company's management indicates that Paul Hudson has stepped down as the CEO. In addition, Sanofi expanded its India GCC by planning to add over 4,500 employees and aims to enhance Accessibility within the pharmaceutical sector.
Sanofi's Dupixent, which is an effective treatment for various ailments, has yielded promising results in Phase III trials.
Significantly, Sanofi decided to drop its plan to develop a next-generation mRNA seasonal flu vaccine and has decided to sell its Medley unit to Brazil’s EMS. The firm faces some criticisms over the CEO's claims regarding the Pfizer RSV vaccine. However, Sanofi continues its contribution to the scientific community with advancements in artificial intelligence in drug discovery, adult vaccines, and autoimmune treatments.
Sanofi News Analytics from Fri, 06 Jun 2025 07:00:00 GMT to Sat, 14 Mar 2026 16:23:17 GMT -
Rating 0
- Innovation 5
- Information 7
- Rumor -3
